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Abstract
The current case management and drug policy of malaria in Nigeria recommended by the Federal 
ministry of health may not be appropriate for all age categories. This suspicion was tested by running a cost 
effectiveness analysis of two possible and alternative strategies: Artemisinin Combination Therapy (ACT) or 
Chloroquine and ACT only if CQ fails (CANACT), in adult non pregnant Nigerians aged 20-45yrs. The result 
confirms that ACT is indeed more effective but also more costly with an incremental cost effectiveness ratio 
(ICER) of  #2,546,527.00 per QALY that is much higher than the estimated upper limit of  #25,000.00 that either 
patients or provider  may be willing to pay.  The CANACT strategy may be the most cost effective strategy in 
this subgroup of Nigerian patients and also provides better value for money.
Keywords: Malaria, Artemisinin Combination Therapy, Chloroquine, Incremental Cost effectiveness, Quality 
adjusted life years, Nigeria
Introduction
Plasmadium falciparum malaria is a potentially disastrous Infection, especially at the extremes of life 
(Gavazzi et al., 2004; WHO, 2008). In such age groups, effective and rapid control of parasitaemia may be life 
saving. Artemisinin and its derivatives are highly effective and rapid schizonticides and are reasonable as first 
line drugs for the treatment of malaria (de Vries and Dien ,1996; Hien and White, 1993). When Artemisinin is 
co-administered with a longer acting and efficacious anti-plasmodia drug with a different mechanism of action (a 
combination known as ACT), a high cure rate usually results (WHO, 2001). ACT is the recommended first line 
medication for the treatment of uncomplicated Plasmadium falciparum malaria, especially in areas where 
resistance to Chloroquine (CQ) and /or sulpadoxine-pyrimethamine is above 10% (WHO, 2006). Resistance to 
CQ in Nigeria is estimated to be between 25.8% (WHO, 2005) and 39.2% (Ukwuoma, 2005). On January 24, 
2005, Nigeria dramatically banned CQ and Sulphadoxine-Pyrimethamine as first line drugs  in the treatment of 
malaria in all age groups (Ukwuoma, 2005). It may be argued that the WHO recommendation has been hastily, 
perhaps canonically,  adopted by Nigeria because evidence that robust cost-effectiveness studies was done as a 
guide to the adoption of ACT for all age groups of patients have not been presented. For an illness that is 
responsible for 60% of outpatient and cost the nation an estimated 132 billion Nigerian Naira (N) per year 
(Ukwuoma, 2005), changes in treatment policies need to be formally justified by careful consideration so as to 
optimize cost versus   effectiveness. In Plasmodium malaria, it is plausible that the cost-effective and therefore 
the best treatment strategy may be different between age groups because age is known to modify diseases and 
treatment outcomes (Bello et al., 2005). The high morbidity and mortality associated with malaria in persons 
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aged under 5 years and over  55 years is  probably  compelling argument for the use of ACT in these age groups. 
This argument may also be true in pregnant adults, epidemic malaria or in non immune persons but the same 
argument may not stand scrutiny in holo-endemic regions when applied to non pregnant adults in the age range 
20-45 yrs (adult Nigerians or AN) who also constitutes about 56% of malaria cases (Bello et al., 2005). In this 
group, a case may be made for CQ as a first line drug irrespective of the current level of resistance because six to 
seven of every ten of patients should respond to CQ while 3-4 will be expected to fail and are the ones who 
really need the ACT. Furthermore, the probability of treatment success or failure to CQ and therefore the need to 
add-on ACT may be determined within 24-48 hrs of starting treatment because, when effective, CQ causes fever 
lyses in this time range (Shapiro and Goldberg, 2001; Mengesha and Makonnen, 1999). One of the expected 
consequences of treatment failure in AN is a longer duration of malaria morbidity because, by adult age, herd 
immunity is usually well established and mortality is extremely rare (Gavazzi et al., 2004). Other considerations 
that may guide decision is that while ACT has high rates of substandard preparations that contain between 
74%and 77% (Atemnkeng et al., 2007, Raufu, 2002) of the value stated by the manufacturer and currently have 
treatment failures of about 1-18% (Ittarat et al., 2003; Ajayi et al., 2008a), CQ has substandard preparations that 
contain 0-87% (Ofonaike et al., 2007) but those that contain above 50% (89% of substandard CQ) of the label 
value are still efficacious in non-resistant parasite because CQ concentrates within parasite vacuoles (Shapiro 
and Goldberg, 2001). Two different strategies may therefore be considered to be available as potential first line 
treatments in adults with uncomplicated malaria namely-ACT or CQ plus ACT when needed (CQ plus as needed 
Artemisinin combination treatment-CANACT). The optimal of these treatment options may be identified after 
formal evaluation by a cost-effectiveness study. This study was conducted for this reason.  
Methodology
The Model
A decision tree based on the model of Goodman et al (2001) but with modified terminal outcomes was 
developed using the software Treeage PRO(R) 2008 (TreeAge Software, Inc., Williams, MA). A state transition 
(Markov) model was then developed using the same software. The intention of the model was to simulate the 
cost-effectiveness of a strategy that involves CANACT with ACT. It was assumed that all initial treatment 
would be outpatient. A Markov cycle length of 3 days was used because it was expected that based on clinical 
response, the next decision in the treatment chain should be made in 72hrs.   Cure was defined as Adequate 
clinical response (ACR) using the WHO criteria (WHO, 2003) while failure was defined as absence of ACR. 
Parasitological response was not factored in because a state transition of 3 days is inconsistent with 
parasitological success that requires at least 28days to declare (WHO/CTD, 1996). Furthermore, anecdotal 
evidence suggests that day 28 parasitological screening is not routine in Nigeria and available evidence suggests
that microscopy is only routinely used in about 21.6% of cases in non research settings (Njuguna and Qader, 
2007).  Quinine was considered as the final treatment option of interest after ACT and therefore the decision 
pathway was terminated after Quinine failure and this was termed worst case scenario (‘Worstcase’) which could 
mean death, long term disability or long term treatment until either of these occurs or cure ensues. The 
probabilities at chance nodes were allocated from published estimates except that it was assumed that the chance
of failure of ACT as first line treatment would be 10% as a consensus between the published clinical failure rate 
of 15-18% in observational studies (Ittarat et al., 2003) and the 1-2% failure rates reported in more formal 
randomized studies (Martensson et al.,2005; Meremikwu et al., 2006; Ajayi et al., 2008b). On the other hand, the 
chance of failure of ACT after treatment with CQ was accepted to be the frequently quoted 2% because ACT 
has been reported to be more effective against CQ resistant than CQ sensitive Plasmadium falciparum (Shapiro 
and Goldberg, 2001).  It was estimated that severe malaria has equal chance of being treated outpatient or in 
patient because which of these events occurs depends on the willingness of the patient to seek secondary or 
tertiary level care and the availability of such level of care. It is therefore reasonable to expect the chances to be 
balanced (i.e. 50:50) in the Nigerian setting. Inpatient Quinine therapy was defined as Quinine plus all other 
drugs that may be co-administered (e.g. Intravenous infusions, Doxicycline etc.) and was therefore allocated a 
1% chance of failure. Because the allocated nodal probabilities are published estimates and unbiased between 
ACT and CANACT, it was expected that minor errors may not influence outcome. However, it was pre-specified 
to perform sensitivity analysis using the various ranges of published estimates of treatment outcomes to test if 
errors in such estimates may affect the results. We tested the outcome between  Chloroquine failure rates of 10 
% to 90 % at 5% intervals. We also tested the outcome between ACT failure rates of 1% to 20 % at 5% intervals.
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Cost
This analysis is expected to provide additional guide for clinical and policy decisions. We, therefore, 
first considered cost and effectiveness from the providers’ perspective. We recognize that only 38% of Nigerian 
patronize government facilities for malaria care (Ejezie et al., 1990), therefore CE from the consumer’s 
perspective was also evaluated. In ideal set ups, doctors, nurses, supplies and administrative costs are defined,
however cost data are extremely hard to estimate in developing economies (Onoka et al., 2007). We therefore 
used a simple imputation costing system (Johnston et al., 1999) by allocating #15000.00 for these cost per cycle 
of  inpatient admission (which we defined as every 3 days) and used simple market survey to quantify the real 
cost of drugs.  All costs were estimated in Nigerian Naira (#) because the study is focused on treatment in 
Nigeria and conclusions are expected to be valid only for the treatment of malaria in Nigeria. The exchange rate 
on the date costing was documented for this study was #154.1 for $1.00 or 0.696 Euros (Worldmate, 2009)
Effectiveness
In the decision tree and Markov model, effectiveness was measured as Quality-Adjusted Life Years 
(QALYs) which provides a numerical measure of health over time and may be estimated as the product of the 
quantity of life gained per treatment episode and the quality. QALY was estimated from both the provider’s and 
the consumer’s perspectives. From published data, an adult Nigerian may develop malaria two times per year
(Olanrewaju and Johnson, 2001). The Quantity of life gained per treatment was therefore estimated as 6 months. 
Age weighing and discounting were not done because these are only important when Disability Adjusted Life 
Years (DALY) is used as the index of effectiveness (Myamoto and  Eraker, 1985; Sassi, 2006). Quality of life 
was estimated from the patients’ perspective. ‘Cure’ was therefore allocated a score of 1 and ‘Worstcase’ a score 
of zero because death is a possible outcome. Quality score for severe malaria in Nigerian was taken as 0.3
(Goodman et al., 2001). Quality score for uncomplicated malaria was estimated to be 0.67±0.26 as determined 
by a pilot study using the visual analogue scale (VAS) on 10 randomly selected male and female Nigerian and 
asking respondents to allocate on a visual scale of 0-100  their estimate of the quality of life when with malaria 
against when fully healthy. Person trade-Off (PTO) method was not used because we agree with the criticism 
that values allocated by expert panels may not represent values of others (i.e. is not patient oriented) and that 
PTO includes forced consistency between questions that are quite different (Bleichrodt and Johannesson, 1996; 
Arnesen and Nord, 1999).  The mean score was used in the models while the standard deviation was used in the
sensitivity analysis. We compared cost effectiveness by using Incremental Cost Effectiveness Ratios (ICER).
Willingness to pay
We used the internationally accepted  $50,000 ICER threshold (Hirth et al., 2000)  for sensitivity 
analysis but used #25000 as the conservative WTP by the provider. This was estimated from the per capita 
income of Nigeria which stood at $2300 in 2008 (Tong, 2008) adjusted by the percentage allocated to the health 
sector in the 2008 and 2009 Nigerian Budget (The Federal Government of Nigeria, 2009).  Also, Jimoh et al 
(2007) have shown that Nigerians are willing to pay (WTP) # 1,112 monthly (i.e. #13344 every year) for the 
treatment of adult malaria. We therefore used this as the WTP for one QALY Gained from the consumers’ 
perspective. We captured all three thresholds in our analysis in order to address the uncertainties of policy 
changes. 
Results
The decision tree, Figure 1, followed the possible outcome of an AN with uncomplicated malaria 
treated with either CANACT or ACT. The cost of the items in the pathway is as listed in Table 1. The 
probability estimates of all components of the tree are as listed in Table 2. CANACT had a CE of #501.1 per 
0.99258 QALY while that of ACT was #1,539.8 per 0.99299 QALY. The ICER of ACT was #2,546,527.00. 
Other CE outcomes are as listed in Table 3. From the calculated (rolled back) tree (Figure 2),if the CANACT  
strategy is chosen, when CQ fails, the best pathway (most CE) pathway then becomes outpatient rather than 
inpatient ACT irrespective of whether the malaria remain uncomplicated or severe ( CE of #1699  per 0.989
QALY for outpatient care compared to #17448 per 0.983 QALY for inpatient care) but when ACT fails, 
inpatient quinine(CE #21200 per 0.974 QALY)  is more CE than outpatient quinine(CE #1250 per 0.016 QALY 
)  in severe malaria while outpatient quinine is more CE if the malaria remain uncomplicated. The optimal 
pathway after ACT remained the same irrespective of whether it was used as first line or backup (second line) 
medication. The result of testing the uncertainties in the failure rates of CQ and ACT are shown in Table 4. From 
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the Monte Carlo simulations, if these strategies are used now and maintained for the next 10 years, CANACT 
dominates ACT at WTP of #1150.00 (Figure 3) to #20,000.00 but no strategy is dominated between WTP of 
#21000 and #7,705,000.00 (Figure 4). The net health benefit of the ACT strategy is never superior to the 
CANACT strategy at all levels of WTP (Figure 5a). At a threshold willingness-to-pay of #25 000 per QALY, 
75% of resources will be optimally utilized with the CANACT strategy compared to 22% with the ACT strategy 
(Figure 5b). From the Markov’s model, when all possible outcomes are considered given the available data at a 
WTP of #25000, the ACT strategy is either less effective and less costly or less effective and more costly 65% of 
the time when compared to the CANACT strategy (Figure 6).
Figure 1: Decision tree used to compare the cost-effectiveness of Artemisinin-based combination therapies 
(ACTs) versus CQ plus as needed ACTs (CANACT).       
     = Decision node,             = Chance node and        = Terminal node
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Figure 2: Rolled back decision tree with best pathway analysis
When the decision tree was rolled back, Treeage 2008(R) picked CANACT as the optimal pathway. This outcome 
did not change even at a willingness to pay #200000 (i.e. when cost was absolutely not an issue). 
     = Decision node,              = Chance node and         = Terminal node
//= crossed out or unfavourable pathway
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Figure 3: Cost-Effectiveness analysis Plot at WTP of #1150 
The analysis was taken at the decision point “Adult Nigerians with Malaria”.  The ACT strategy is obviously 
dominated by CANACT. The graph is from the consumer’s perspective and captures the current program where 
adult Nigerians pay for their own treatment. The WTP of #1150 by Nigerians for the treatment of malaria 
reflects the findings of Jimoh et al (2007).
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Figure 4: Cost-Effectiveness analysis Plot at WTP #25,000.00 - #7,705,000.00
The analysis was taken at the decision point “Adult Nigerians with Malaria”.  This plot captures a government 
(provider) sponsored program. ACT is then more effective but also much more costly than CANACT. This 
relationship remains the same between WTP of #25,000.00 to #7,705,000.00 (when cost implication is 
considered to be of little consideration).  
Figure 5a: Net Health Benefit (NHB) and willingness –to- pay
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The graph displays the NHB (effectiveness –Cost/ WTP) of each strategy at various levels of WTP. NHB 
describe the uncertainties in CE models and may specify the WTP at which a given strategy becomes more CE 
than the comparator. The most CE comparator is the one with the highest NHB at a given WTP.  In this graph, 
the NHB of the ACT strategy is either inferior or equal to that of the CANACT strategy at all levels of WTP 
examined (up to #7,705,000.00). The plots have been truncated at #25000 because the two lines are equal 
beyond a WTP of #25000.
Figure 5b. Net health benefit optimality graph based on a Willingness-to-pay of #25000 
The graph displays against each option (strategy) the percentage of 1000 Monte Carlos Micro stimulation in 
which that option had the highest net health benefit. CANACT had 75% optimal benefit and ACT had 22%.
More value for money is obtained from the CANACT than the ACT strategy.
Figure 6. ICE scatter plot of ACT Versus CANACT strategy
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The From the simulation statistics, ACT is more costly and more effective than CANACT at WTP of #25000. 
Following standard protocol (Fenwick et al., 2004), CANACT was therefore used as the baseline strategy and 
ACT as the comparator. The ellipse describes the probability that ACT is cost effective compared to CANACT 
(the origin) given the available data at the specified WTP. WTP line in the graph intersects points having the 
specified ICER value, and the region below the line includes cost-effective points. The ellipse falls within all of 
the quadrants, with 31% contained within the NW quadrant (i.e. dominated) and 28% within NE quadrant (i.e. 
more effective and more costly) and with only 35% cost effective (below the WTP slanting line).  This plot 
makes a strong case for the baseline strategy (CANACT). 
Table 1: Estimates of cost used for the decision tree
Item Cost per unit(#) Source
Quinine Tablet #25.00 Market survey by BSO and HA
Quinine Injection #50.00 Market survey by BSO and HA
Chloroquine  Tablet #5.00 Market survey by BSO and HA
Chloroquine Injection #15.00 Market survey by BSO and HA
Artheter Injection #250.00 Market survey by BSO and HA
Artesunate Injection #350.00 Market survey by BSO and HA
Needles & syringes #10.00 Market survey by BSO and HA
Intravenous fluid per 500mls #150.00 Market survey by BSO and HA
Giving set #25.00 Market survey by BSO and HA
Plaster #60.00 Market survey by BSO and HA
Cannula #60.00 Market survey by BSO and HA
Inpatient Quinine care (including 
fluids , Doxicycline)
#4925.00 Hospital survey by BSO  and AYB
Non drug cost of inpatient care #15000.00 Best anecdotal estimate by BSO, 
CA and AYB.
BSO=Bello Shaibu Oricha, CA=Chika Aminu, AYB=Aishatu Yahaya Bello, HA=Hauwa Abdullahi
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Table 2:  Estimates of probabilities used for the decision tree
Input variable Type of 
probability 
distribution
Best estimate in 
Nigeria(%) and 
source
Lowest
estimate in 
Nigeria (%) 
and source
Highest 
probable 
estimate 
anywhere (%)
and source
Estimate
used for 
tree (%)
Risk of CQ 
failure
Point estimate 38.0; 
Ogungbamigbe et 
al., 2008
13.4; 
Olarewaju,
2001; Ekanem 
et al., 2000
88.0; 
WHO 2000; 
WHO 2008.
35.0
Risk of ACT 
failure
Point estimate 2.0;
Meremikwu et al., 
2006
1.0;
Ajayi  et al., 
2008
18.0;
Ittarat et al.,2003
10.0
Risk of Quinine 
failure
Point estimate 2.0;
PrayGod et 
al.,2008
14.7;
Adagu et 
al.,1995
21.0;
Yeka et al.,2009
10.0
Risk of ACT 
failure in CQ 
resistant malaria
Point estimate 2.0;
Meremikwu et al., 
2006
1.0;
Ajayi  et al., 
2008
2.0
Meremikwu et al., 
2006
2.0
Risk of severe 
malaria in AN
Anecdotal 
estimate
1.0;
Snow et al,1999
1.0;
Snow et 
al,1999
5.0;
 Makani et al., 
2003.
5.0
Risk of death 
from 
U/MDRSPfm in 
AN
Point estimate NA NA 100.0 ; 
WHO,2000
99.0
NA=Not available, AN = Adult Nigerians, U/MDRpfm= Untreated/multidrug resistant severe Plasmadium 
falciparum malaria. 
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Table 3. CE table of CANACT versus ACT
Strategy Cost
(#)
Incremental 
Cost
Effectiveness
(QALY)
Incremental 
Effectiveness
Cost-
Effectiveness
(#/QALY)
Incremental 
Cost-
Effectiveness
ratio(#/QALY)
CANACT  501.1 0.99258 505.00
ACT 1,539.8 1,038.6 0.99299 0.00041 1551.00 2,546,527.00
Table 4. Sensitivity analysis at various levels of predicted Artemisinin and Chloroquine resistance. 
Level of resistance 
to Chloroquine (%)
Level of 
resistance to 
ACT (%)
Cost –effectiveness 
of ACT strategy 
(#/QALY)
Cost-Effectiveness 
of CANACT 
strategy (#/QALY)
Optimal Strategy
10 10 1540/0.993 179/0.994 CANACT
20 10 1540/0.993 303/0.993 CANACT
30 10 1540/0.993 437/0.993 CANACT
40 10 1540/0.993 566/0.992 CANACT
50 10 1540/0.993 694/0/992 CANACT
60 10 1540/0.993 823/0.991 CANACT
70 10 1540/0.993 952/0.991 CANACT
75 10 1540/0.993 1017/0.990 CANACT
80 10 1540/0.993 1081/0.990 ACT
85 10 1540/0.993 1146/0.990 ACT
75 0 1250/0.995 1017/0.990 ACT
70 0 1250/0.995 952/0.991 CANACT
  
This sensitivity analysis presented in this table  was done at WTP of #200,000 -#7,705,000.00
Discussion
This study has confirmed that the ACT strategy is indeed more effective in adult non pregnant 
Nigerians than the CANACT strategy but that it is also much more costly; with an ICER of #2,546,527.00 per 
QALY gained.  This ICER is also much below the internationally accepted ICER limit of $50,000.00 (or 
#7,705,000.00 at the current exchange rate of #154.1 per $). This study, therefore, appears to support the 
adoption of ACT as the first line strategy by the Nigerian Government.  A careful review of the result using 
contemporary pharmacoeconomic principles may suggest otherwise. A number of commentators have suggested 
that the goal of the health intervention is to optimize health gain for limited funds (Claxton et al., 2002) and that, 
given this goal, it is the likely value of an intervention that should guide decision (Claxton et al., 2002; O’Hagan 
et al., 2000). A continuing argument is on how much value we may put to health. The United States of America 
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(USA)’s ICER threshold of $50,000.00 per QALY as ideal has been used as the standard WTP internationally
(Hirth et al., 2000)  but this has been criticized as flawed (Ubel et al., 2003). For this reason, various countries 
and organizations have used widely different and less ambitious thresholds (Devlin and Parkin, 2004; George et 
al., 2001; Hoch, 2004).  If the provider is willing to pay the standard ICER threshold, then ACT strategy is the 
best strategy. This study has revealed than when consumers have to pay for care and the government is only 
WTP a fraction of the standard ICER, the CANACT strategy dominates ACT at the current level of CQ 
resistance. Also, the CANACT strategy remains dominant until either the background resistance to CQ is at or 
above 75% and the failure rate of ACT is zero or the failure rate of ACT is at or above 10% and the failure rate 
of CQ is 80%. This study has provided strong evidence that even if the provider was willing to pay the standard 
ICER threshold more value for money is obtained with the CANACT strategy at the current CQ failure rates
because both the optimality analysis and NHB favours it.. 
It may be argued that irrespective of policy statements, whether the policy is ideal for a situation is best 
evaluated from reality. Our result has presented that given the WTP of the Nigerian public for malaria as shown 
by Jimoh et al. (2007), the ACT strategy is the wrong strategy for AN. This is may be one of the reasons for the
poor compliance to the ACT policy by physicians and patients (Ajayi et al., 2008b; Bosman and Kamini, 2007). 
If policies are not supported financially, it is probably more likely that the interplay of the payers’ value versus
ability dictates which policy is executed.
The optimal pathway shown in the rolled back decision tree further illuminates the role of CE in 
guiding even treatment algorithms, given that resources are restricted. Again, the pathway that is chosen depends 
on the WTP. Developed nations may disregard cost values below #7,705,000.00 per QALY and the WHO may 
be right to have recommended policies to countries based on the non-inferiority principle, especially when such 
policies are well funded and supported ex-government, but this study has shown that adoption by less developed 
economies is best based on pharmaco-economic data.   
Conclusion
Given the current levels of treatment failures of CQ, both CANACT and ACT strategy remain CE 
treatment strategies in AN with uncomplicated malaria. The banning of CQ by the Nigerian government was 
probably hasty and is not supported by the current level of government funds available for malaria control. In 
AN, the CANACT strategy gives more value for money and may be enhanced by adequate control of counterfeit 
medications. It may be important to conduct further studies to broadly define the optimal strategy for other age 
categories as guide to resource optimization.
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